NASDAQ:CMRX
Chimerix Stock News
$0.95
+0.0027 (+0.284%)
At Close: May 03, 2024
Why Chimerix Stock Skyrocketed on Friday
07:48pm, Friday, 08'th Jan 2021
A new acquisition could be quite the shot in the arm for the company.
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
06:00am, Friday, 08'th Jan 2021
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma
Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
07:00am, Monday, 07'th Dec 2020
FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021 FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021
Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript
03:16am, Sunday, 08'th Nov 2020
Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript
Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
04:01pm, Thursday, 05'th Nov 2020
DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, to
Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020
07:00am, Thursday, 29'th Oct 2020
DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, to
65,768 Shares in Chimerix Inc (NASDAQ:CMRX) Purchased by Public Employees Retirement System of Ohio
06:08am, Sunday, 27'th Sep 2020
Public Employees Retirement System of Ohio acquired a new position in shares of Chimerix Inc (NASDAQ:CMRX) in the second quarter, according to the company in its most recent 13F filing with the Securi
Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
12:25pm, Monday, 10'th Aug 2020
Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Chimerix Q2 Earnings
11:28am, Monday, 10'th Aug 2020
Shares of Chimerix (NASDAQ:CMRX) were flat in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 54.29% year over year to ($0.16), which beat the estima
Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update
11:00am, Monday, 10'th Aug 2020
– Completion of BCV NDA Rolling Submission Planned for Third Quarter 2020 – – Currently Enrolling Phase 2/3 Study of DSTAT in Patients with COVID-19; Phase 2 Enrollment Completion Expected
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020
12:00pm, Monday, 03'rd Aug 2020
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, to
Will Chimerix (NASDAQ:CMRX) Spend Its Cash Wisely?
04:22pm, Wednesday, 15'th Jul 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Here is What Hedge Funds Think About Chimerix Inc (CMRX)
06:43pm, Sunday, 05'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer
11:00am, Monday, 22'nd Jun 2020
Chimerix (CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Allen Melemed, M.D., M
